Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04003246 · ClinicalTrials.gov registry record · Phase 2
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04003246 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04003246, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
Interventions
- RADIATION Thoracic RT and Durvalumab
- DRUG Consolidative Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-04-03 |
| Est. Completion | 2024-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04003246
The ClinicalTrials.gov registry entry for NCT04003246 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thoracic RT and Durvalumab is the first listed.
NCT04003246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04003246 about?
NCT04003246 is a clinical study titled "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer". Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT04003246?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-04-03. Estimated completion is 2024-11-05.
What interventions are being tested in trial NCT04003246?
The interventions under investigation include: Thoracic RT and Durvalumab (RADIATION), Consolidative Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04003246?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.